Company intelligence
Oxeia Biopharmaceuticals Inc
Oxeia Biopharmaceuticals develops novel therapeutics for patients with concussions. Because rest is not enough
About Oxeia Biopharmaceuticals Inc
Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that began a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients.
Verified activity
Signals from Oxeia Biopharmaceuticals Inc
4 published signals
Capital & Finance
Oxeia Biopharmaceuticals Inc raised funds for Phase 2b of OXE103, which closes on September 24, 2026.
Reported by Oxeia Biopharmaceuticals Inc
Legal & Regulatory
Oxeia Biopharmaceuticals Inc holds three issued patent families on treating concussion with ghrelin, licensed from UCSD, plus its own dosing and trial design.
Reported by Oxeia Biopharmaceuticals Inc
Capital & Finance
Oxeia Biopharmaceuticals Inc raised funds for Phase 2b of its concussion treatment trial, closing on September 24.
Reported by Oxeia Biopharmaceuticals Inc
Capital & Finance
Oxeia Biopharmaceuticals Inc published in Neurotrauma Reports that In Phase 2a, OXE103 showed an 85% responder rate against 33% on standard care.
Reported by Oxeia Biopharmaceuticals Inc